Analysis and evaluation of the safety usage of strontium renelate at a regional teaching hospital of southern taiwan
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Poster
- By: LIU, Chientzu (E-DA Hospital, Pharmacy Department, Kaohsiung city, China Taiwan)
- Co-author(s): Lee, Ani (E-DA Hospital, Kaohsiung city, China Taiwan)
Lin, Meifang (E-DA Hospital, Kaohsiung city, China Taiwan)
Back in April of 2013, European Medicines Agency (EMA) announced that Strontium renelate increased the risk of serious heart problems. In May FDA also announced that the drug is not recommended for patients who with a current or past history of ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease, or in.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.